Research ArticleCANCER

Syrosingopine sensitizes cancer cells to killing by metformin

See allHide authors and affiliations

Science Advances  23 Dec 2016:
Vol. 2, no. 12, e1601756
DOI: 10.1126/sciadv.1601756

You are currently viewing the abstract.

View Full Text

Abstract

We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells. This effect is unrelated to syrosingopine’s known role as an inhibitor of the vesicular monoamine transporters. Syrosingopine binds to the glycolytic enzyme α-enolase in vitro, and the expression of the γ-enolase isoform correlates with nonresponsiveness to the drug combination. Syrosingopine sensitized cancer cells to metformin and its more potent derivative phenformin far below the individual toxic threshold of each compound. Thus, combining syrosingopine and codrugs is a promising therapeutic strategy for clinical application for the treatment of cancer.

Keywords
  • metformin
  • biguanide
  • syrosingopine
  • Mitochondria
  • Cancer
  • metabolism
  • synthetic lethality

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

View Full Text